Study Shows Nirmatrelvir–Ritonavir No More Effective Than Placebo for COVID-19 Symptom Relief

, may not be particularly helpful for patients who are not at high risk for severe COVID-19 . However, although the rate of hospitalization and death from any cause was low overall, the group that received Paxlovid had a reduced rate compared with people in the placebo group, according to the researchers.

"Clearly, the benefit observed among unvaccinated high-risk persons does not extend to those at lower risk for severe Covid-19," wrote Rajesh T. Gandhi, MD, and Martin Hirsch, MD, both from Massachusetts General Hospital in Boston,The time from onset to relief of COVID-19 symptoms — including cough, shortness of breath, body aches, and chills — did not differ significantly between the two study groups, the researchers reported.

The study's limitations include that the statistical analysis of COVID-19–related hospitalizations or death from any cause was only descriptive, "because the results for the primary efficacy end point were not significant," the authors wrote. Participants who were vaccinated and at high risk were also enrolled regardless of when they had last had a vaccine dose. Furthermore, Paxlovid has a telltale taste, which may have affected the blinding. Finally, the trial was started when the B.1.617.2 variant was predominant.

Gandhi and Hirsch pointed out that only 5% of participants in the trial were older than 65 years and that other than risk factors such as"As with many medical interventions, there is likely to be a gradient of benefit for nirmatrelvir–ritonavir, with the patients at highest risk for progression most likely to derive the greatest benefit," Gandhi and Hirsch wrote in the editorial.

2019 Novel Coronavirus 2019-Ncov Wuhan Coronavirus Human Coronavirus HKU1 Human Coronavirus OC43 Hcov-OC43 Human Coronavirus 229E Hcov-229E Corona Virus Covid19 Novel Coronavirus SARS-Cov-2 Pandemic COVID-19 And Geriatrics Coronavirus And Geriatrics Immunizations Vaccination Immunocompromise Immunocompromised Immunosuppression Antiviral Famciclovir Valacyclovir

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Viking Therapeutics' Weight-loss Tablet Shows Promise in Small StudyViking Therapeutics' experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations...
Source: Medscape - 🏆 386. / 55 Read more »

Survey study shows workers with more flexibility and job security have better mental healthA team of community health specialists at the Boston University School of Public Health, working with a psychiatrist from Brown University, has found evidence that suggests workers who have more job flexibility and security tend to have better mental health overall.
Source: physorg_com - 🏆 388. / 55 Read more »

The era of 'climateflation' is here, study showsThe data suggests climate change is rippling through entire economies.
Source: axios - 🏆 302. / 63 Read more »

Diet and Sugary Drinks Linked to Higher Atrial Fibrillation Risk, Study ShowsPeople who frequently drink beverages made with sugar or artificial sweeteners could carry a higher risk of atrial fibrillation, a potentially dangerous heart condition, new research shows.
Source: Health - 🏆 396. / 53 Read more »

Genome study shows humans pass more viruses to animals than we catch from themHumans pass on more viruses to domestic and wild animals than we catch from them, according to a major new analysis of viral genomes by UCL researchers.
Source: physorg_com - 🏆 388. / 55 Read more »

New blood test shows high accuracy for colorectal cancer detection, study finds: ‘Not interchangeable’A study published in The New England Journal of Medicine says a simple blood test could detect colorectal cancer (CRC) with over 80% accuracy. The study involved 8,000 people; experts weighed in.
Source: FoxNews - 🏆 9. / 87 Read more »